U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Guidance for Industry: Policy Related to Cranberry Products with Added Flavorings
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Guidance for Industry: Policy Related to Cranberry Products with Added Flavorings August 2019

Final
Docket Number:
FDA-2018-D-0075
Issued by:
Guidance Issuing Office
Office of Nutrition and Food Labeling

The purpose of this guidance is to advise manufacturers of certain dried cranberry products  with added flavorings of our intent to exercise enforcement discretion until July 1, 2020, for their compliance with the updated labeling requirements set forth in two final rules published in the Federal Register of May 27, 2016 entitled, “Food Labeling:  Revision of the Nutrition and Supplement Facts Labels” (hereafter referred to as “Nutrition Facts label final rule” (81 FR 33742)) (see 21 CFR 101) and “Food Labeling: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion;  Dual-Column Labeling; Updating, Modifying, and Establishing Certain Reference Amounts Customarily Consumed; Serving Size for Breath Mints; and Technical Amendments” (hereafter referred to as the “Serving Size final rule” (81 FR 34000)) (see 21 CFR 101).

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities.  Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

Download the Guidance

Related Resources


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2018-D-0075.